Revised Document for the quarter and financial year ended on 31st March,2025 (Regulation 30 and 33 of the SEBI(Listing Obligation and Disclosure Requirement)Regulation,2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences has refiled its audited results for Q4 and FY25 after discovering that the quarterly figures were omitted from its earlier submission; the company states this was an oversight and not a restatement of underlying numbers. For the full year ended March 31, 2025, revenue from operations fell to Rs 10,487.65 lakh from Rs 11,892.08 lakh in FY24, a decline of about 12%. Total expenses rose to Rs 11,370.20 lakh, pushing the company to a pre-tax loss of Rs 718.37 lakh versus a profit of Rs 1,363.42 lakh last year, and a net loss of Rs 530.87 lakh (EPS of minus Rs 1.12) versus a profit of Rs 961.24 lakh (EPS Rs 2.03) in FY24. Standalone Q4 (Jan–Mar 2025) results showed revenue of Rs 3,824.38 lakh, pre-tax profit of Rs 634.18 lakh and net profit of Rs 199.17 lakh (EPS Rs 0.42), indicating the bulk of the FY pain came from earlier quarters. The balance sheet strengthened, with total equity rising to Rs 996.61 lakh from just Rs 33.10 lakh a year earlier. Total borrowings stood at about Rs 3,256 lakh against equity of Rs 997 lakh (D/E roughly 3.3x). Operating cash flow was healthy at Rs 2,131.44 lakh (vs Rs 1,453.48 lakh). The auditor issued an unqualified opinion.
Shareholders should note the sharp swing from profit to loss in FY25 and the still-elevated debt levels, even though the auditor's report is clean and Q4 returned to profit. The revision is administrative but may dent confidence in the company's reporting controls.